Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1978 Jul;75(7):3422–3426. doi: 10.1073/pnas.75.7.3422

Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process.

D B Drachman, C W Angus, R N Adams, I Kao
PMCID: PMC392789  PMID: 277944

Abstract

Antibodies in the sera of patients with myasthenia gravis are believed to play an important role in the pathogenesis of the disorder. They have recently been shown to accelerate the degradation of acetylcholine receptors in cultured mammalian skeletal muscle and at intact neuromuscular junctions. To elucidate the mechanism of the antibody-accelerated degradation process, we have prepared cultures in which one set of acetylcholine receptors was exposed to myasthenic immunoglobulin while a second set of acetylcholine receptors, newly incorporated after exposure to the immunoglobulins, was not. The set of acetylcholine receptors with bound myasthenic immunoglobulin was degraded at 2 to 3 times the normal rate, while the second set of acetylcholine receptors without bound immunoglobulin was degraded at the control rate. This suggest that the binding of antibody from myasthenic patients alters the acetylcholine receptors in some way that causes them to be selected for preferential degradation by the muscle cells. New synthesis and incorporation of the acetyl-choline receptors into the surface membrane of cultured skeletal muscle was unaffected by exposure to myasthenic immunoglobulin.

Full text

PDF
3422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albuquerque E. X., Rash J. E., Mayer R. F., Satterfield J. R. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol. 1976 Jun;51(3):536–563. doi: 10.1016/0014-4886(76)90179-5. [DOI] [PubMed] [Google Scholar]
  2. Almon R. R., Andrew C. G., Appel S. H. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974 Oct 4;186(4158):55–57. doi: 10.1126/science.186.4158.55. [DOI] [PubMed] [Google Scholar]
  3. Appel S. H., Anwyl R., McAdams M. W., Elias S. Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A. 1977 May;74(5):2130–2134. doi: 10.1073/pnas.74.5.2130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bender A. N., Ringel S. P., Engel W. K., Daniels M. P., Vogel Z. Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet. 1975 Mar 15;1(7907):607–609. doi: 10.1016/s0140-6736(75)91886-3. [DOI] [PubMed] [Google Scholar]
  5. Berg D. K., Hall Z. W. Loss of alpha-bungarotoxin from junctional and extrajunctional acetylcholine receptors in rat diaphragm muscle in vivo and in organ culture. J Physiol. 1975 Nov;252(3):771–789. doi: 10.1113/jphysiol.1975.sp011169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bevan S., Kullberg R. W., Heinemann S. F. Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture. Nature. 1977 May 19;267(5608):263–265. doi: 10.1038/267263a0. [DOI] [PubMed] [Google Scholar]
  7. Devreotes P. N., Fambrough D. M. Acetylcholine receptor turnover in membranes of developing muscle fibers. J Cell Biol. 1975 May;65(2):335–358. doi: 10.1083/jcb.65.2.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Devreotes P. N., Fambrough D. M. Synthesis of acetylcholine receptors by cultured chick myotubes and denervated mouse extensor digitorum longus muscles. Proc Natl Acad Sci U S A. 1976 Jan;73(1):161–164. doi: 10.1073/pnas.73.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Devreotes P. N., Fambrough D. M. Turnover of acetylcholine receptors in skeletal muscle. Cold Spring Harb Symp Quant Biol. 1976;40:237–251. doi: 10.1101/sqb.1976.040.01.025. [DOI] [PubMed] [Google Scholar]
  10. Drachman D. B., Angus C. W., Adams R. N., Michelson J. D., Hoffman G. J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med. 1978 May 18;298(20):1116–1122. doi: 10.1056/NEJM197805182982004. [DOI] [PubMed] [Google Scholar]
  11. Drachman D. B., Kao I., Pestronk A., Toyka K. V. Myasthenia gravis as a receptor disorder. Ann N Y Acad Sci. 1976;274:226–234. doi: 10.1111/j.1749-6632.1976.tb47688.x. [DOI] [PubMed] [Google Scholar]
  12. Drachman D. B. Myasthenia gravis (first of two parts). N Engl J Med. 1978 Jan 19;298(3):136–142. doi: 10.1056/NEJM197801192980305. [DOI] [PubMed] [Google Scholar]
  13. Engel A. G., Lindstrom J. M., Lambert E. H., Lennon V. A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology. 1977 Apr;27(4):307–315. doi: 10.1212/wnl.27.4.307. [DOI] [PubMed] [Google Scholar]
  14. Fambrough D. M., Drachman D. B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science. 1973 Oct 19;182(4109):293–295. doi: 10.1126/science.182.4109.293. [DOI] [PubMed] [Google Scholar]
  15. Gavin J. R., 3rd, Roth J., Neville D. M., Jr, de Meyts P., Buell D. N. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci U S A. 1974 Jan;71(1):84–88. doi: 10.1073/pnas.71.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Green D. P., Miledi R., Perez de la Mora M., Vincent A. Acetylcholine receptors. Philos Trans R Soc Lond B Biol Sci. 1975 Jun 10;270(908):551–559. doi: 10.1098/rstb.1975.0031. [DOI] [PubMed] [Google Scholar]
  17. Kao I., Drachman D. B. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977 Apr 29;196(4289):527–529. doi: 10.1126/science.850793. [DOI] [PubMed] [Google Scholar]
  18. Lennon V. A. Immunology of the acetylcholine receptor. Immunol Commun. 1976;5(4):323–344. doi: 10.3109/08820137609044283. [DOI] [PubMed] [Google Scholar]
  19. Lindstrom J. M., Seybold M. E., Lennon V. A., Whittingham S., Duane D. D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976 Nov;26(11):1054–1059. doi: 10.1212/wnl.26.11.1054. [DOI] [PubMed] [Google Scholar]
  20. Merlie J. P., Changeux J. P., Gros F. Acetylcholine receptor degradation measured by pulse chase labelling. Nature. 1976 Nov 4;264(5581):74–76. doi: 10.1038/264074a0. [DOI] [PubMed] [Google Scholar]
  21. Patrick J., McMillan J., Wolfson H., O'Brien J. C. Acetylcholine receptor metabolism in a nonfusing muscle cell line. J Biol Chem. 1977 Mar 25;252(6):2143–2153. [PubMed] [Google Scholar]
  22. Satyamurti S., Drachman D. B., Slone F. Blockade of acetylcholine receptors: a model of myasthenia gravis. Science. 1975 Mar 14;187(4180):955–957. doi: 10.1126/science.1145181. [DOI] [PubMed] [Google Scholar]
  23. Toyka K. V., Brachman D. B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975 Oct 24;190(4212):397–399. doi: 10.1126/science.1179220. [DOI] [PubMed] [Google Scholar]
  24. Toyka K. V., Drachman D. B., Griffin D. E., Pestronk A., Winkelstein J. A., Fishbeck K. H., Kao I. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977 Jan 20;296(3):125–131. doi: 10.1056/NEJM197701202960301. [DOI] [PubMed] [Google Scholar]
  25. de Meyts P., Roth J., Neville D. M., Jr, Gavin J. R., 3rd, Lesniak M. A. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun. 1973 Nov 1;55(1):154–161. doi: 10.1016/s0006-291x(73)80072-5. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES